Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NASDAQ: NRIX), filed a Form 4 on August 5, 2026, reporting the sale of 4,111 shares of common stock on August 4, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • First sale: 1,500 shares disposed of at a weighted average price of $23.8684, with individual sale prices ranging from $23.42 to $24.38.
  • Second sale: 2,611 shares disposed of at a weighted average price of $24.6415, with individual sale prices ranging from $24.43 to $24.83.
  • 10b5-1 plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
  • Remaining ownership: Following the transactions, Hansen directly beneficially owned 117,227 shares of common stock.
  • Signed by attorney-in-fact: The form was signed by Daniel Burbach as attorney-in-fact for Gwenn Hansen on August 5, 2026.

Nurix Therapeutics CSO Reports Two Common Stock Sales on August 4, 2026

According to the filing, Gwenn Hansen, identified as Chief Scientific Officer of Nurix Therapeutics, Inc., sold a total of 4,111 shares of common stock on August 4, 2026. The transactions are reported under transaction code "S" and were carried out directly. Both sales were made pursuant to a Rule 10b5-1 trading plan previously adopted by Hansen, as noted in the filing's explanation of responses.

The first transaction involved the disposal of 1,500 shares at a weighted average sale price of $23.8684. The filing states that the lowest price in that tranche was $23.42 and the highest was $24.38. Following that sale, Hansen's direct beneficial ownership stood at 119,838 shares. The second transaction covered 2,611 shares at a weighted average of $24.6415, with prices ranging from $24.43 to $24.83. After both transactions were completed, beneficial ownership totaled 117,227 shares, held directly.

The filing notes that Hansen "undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein." No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

The Form 4 discloses two open-market sales of Nurix Therapeutics common stock by Chief Scientific Officer Gwenn Hansen on August 4, 2026, totaling 4,111 shares, executed under a pre-established Rule 10b5-1 plan, leaving Hansen with 117,227 shares directly owned.